Trending: U.K. Regulator to Launch Expanded Review into Vodafone U.K.'s Joint Venture With Three
1213 GMT - The U.K. Competition and Markets Authority is among the most mentioned topics across news items over the past five hours, according to Factiva data, after the regulator said it would launch a deep review into the planned joint venture between Vodafone U.K. and Three U.K. unless they come up with a solution to its concerns. The regulator said that it believes the deal could result in higher prices for customers and impact investment in U.K. mobile networks. "Whilst Vodafone and Three have made a number of claims about how their deal is good for competition and investment, the CMA has not seen sufficient evidence to date to back these claims," CMA's Julie Bon said. The companies said that the review was an expected step in the process and they looked forward to engaging constructively with the regulator to set out the benefits of the deal. They have five working days to offer a solution otherwise the CMA will refer the deal for a deeper probe. Vodafone shares were up 2.2% at 69.00 pence. Dow Jones & Co. owns Factiva. ( najat.kantouar@wsj.com)
(END) Dow Jones Newswires
March 22, 2024 09:01 ET (13:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast